{"commentary":{"count":105,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":39,"youtube":33,"podcast":33},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03698019\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT03698019","nct_id":"NCT03698019","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct03698019. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Within 17 days (preferably within 14 days) days after IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 18 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood throughout the study and MRI or CT on study.","label":"Arm I (adjuvant pembrolizumab)","type":"EXPERIMENTAL"},{"description":"Patients receive pembrolizumab IV over 30 minutes on day 1 every 3 weeks for 3 cycles, then undergo surgery within 3 weeks. Within 84 days, patients receive pembrolizumab IV over 30 minutes every 3 weeks for 15 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood throughout the study and MRI or CT on study.","label":"Arm II (adjuvant and neoadjuvant pembrolizumab)","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2026-10-30","type":"ESTIMATED"},"conditions":["Acral Lentiginous Melanoma","Clinical Stage III Cutaneous Melanoma AJCC v8","Clinical Stage IV Cutaneous Melanoma AJCC v8","Mucosal Melanoma"],"enrollment":{"count":313,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Biospecimen Collection","type":"PROCEDURE"},{"name":"Computed Tomography","type":"PROCEDURE"},{"name":"Magnetic Resonance Imaging","type":"PROCEDURE"},{"name":"Pembrolizumab","type":"BIOLOGICAL"},{"name":"Therapeutic Conventional Surgery","type":"PROCEDURE"}],"last_update":"2026-08-04","lead_sponsor":"National Cancer Institute (NCI)","official_title":"A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2022-09-01","type":"ACTUAL"},"primary_outcomes":[{"measure":"Two-Year Event-Free Survival Rate","timeFrame":"2 years"}],"references":[{"citation":"Mangana J, Ozdemir BC, Mihic-Probst D, Siano M, Metaxas Y, Maul LV, Hunger RE, Lindenblatt N, Olariu R, Von Moos R, Balermpas P, Schiappacase L, Mangas C, Michielin O, Dummer R. The updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma. Swiss Med Wkly. 2025 Jul 8;155:4210. doi: 10.57187/s.4210.","pmid":"40811146","type":"DERIVED"},{"citation":"Long GV, Menzies AM, Scolyer RA. Neoadjuvant Checkpoint Immunotherapy and Melanoma: The Time Is Now. J Clin Oncol. 2023 Jun 10;41(17):3236-3248. doi: 10.1200/JCO.22.02575. Epub 2023 Apr 27.","pmid":"37104746","type":"DERIVED"},{"citation":"Patel SP, Othus M, Chen Y, Wright GP Jr, Yost KJ, Hyngstrom JR, Hu-Lieskovan S, Lao CD, Fecher LA, Truong TG, Eisenstein JL, Chandra S, Sosman JA, Kendra KL, Wu RC, Devoe CE, Deutsch GB, Hegde A, Khalil M, Mangla A, Reese AM, Ross MI, Poklepovic AS, Phan GQ, Onitilo AA, Yasar DG, Powers BC, Doolittle GC, In GK, Kokot N, Gibney GT, Atkins MB, Shaheen M, Warneke JA, Ikeguchi A, Najera JE, Chmielowski B, Crompton JG, Floyd JD, Hsueh E, Margolin KA, Chow WA, Grossmann KF, Dietrich E, Prieto VG, Lowe MC, Buchbinder EI, Kirkwood JM, Korde L, Moon J, Sharon E, Sondak VK, Ribas A. Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. N Engl J Med. 2023 Mar 2;388(9):813-823. doi: 10.1056/NEJMoa2211437.","pmid":"36856617","type":"DERIVED"},{"citation":"Gorry C, McCullagh L, O'Donnell H, Barrett S, Schmitz S, Barry M, Curtin K, Beausang E, Barry R, Coyne I. Neoadjuvant treatment for stage III and IV cutaneous melanoma. Cochrane Database Syst Rev. 2023 Jan 17;1(1):CD012974. doi: 10.1002/14651858.CD012974.pub2.","pmid":"36648215","type":"DERIVED"}],"start_date":{"date":"2019-02-15","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma","url":"https://clinicaltrials.gov/study/NCT03698019"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct03698019"}